SEQUENCE LISTING

<110> Bayer AG, BHC

<120> Diagnostics and Therapeutics for Diseases Associated with Arginyl Aminopeptidase RNPEP (RNPEP)

<130> Le A 36 899

<160> 5

<170> PatentIn version 3.1

<210> 1

<211> 2400

<212> DNA

<213> Homo sapiens

<400> 1

cacgaggcca tggcgagcgg cgagcattcc cccggcagcg cgcggcccgg cggccgctgc 60 acteegegea ggetgeggee getgeactee gegeaggetg tggaegtgge eteggeetee 120 aactteeggg cetttgaget getgeaettg eacetggace tgegggetga gttegggeet 180 ccagggcccg gcgcagggag ccgggggctg agcggcaccg cggtcctgga cctgcgctgc 240 ctggagcccg agggcgccgc cgagctgcgg ctggactcgc acccgtgcct ggaggtgacg 300 geggeggege tgeggeggga geggeeegge teggaggage egeetgegga geeegtgage 360 ttctacacgc agcccttctc gcactatggc caggccctgt gcgtgtcctt cccgcagccc 420 tgccgcgccg ccgagcgcct ccaggtgctg ctcacctacc gcgtcgggga gggaccccgg 480 gtttgctggg tggctcccga gcagacagca ggaaagaaga agcccttcgt gtacacccag 540 ggccaggctg tcctaaaccg ggccttcttc ccttgcttcg acacgcctgc tgttaaatac 600 aagtattcag ctcttattga ggtcccagat ggcttcacag ctgtgatgag tgcaagacct 660 ggggagaaga gaggtccaaa taagttcttc ttccagatgt gtcagcccat cccctcctat 720 ctgatagett tggccategg agatetggtt teggetgaag ttggacecag gageegggtg 780 tgggctgagc cctgcctgat tgatgctgcc aaggagtaca acggggtgat agaagaattt 840 ttggcaacag gagagaaget ttttggacet tatgtttggg gaaggtatga ettgetette 900 atgccaccgt cetttecatt tggaggaatg gagaaccett gtetgacett tgteaccece 960 tgcctgctag ctggggaccg ctccttggca gatgtcatca tccatgagat ctcccacagt 1020 tggtttggga acctggtcac caacgccaac tggggtgaat tctggctcaa tgaaggtttc 1080 accatgtacg cecagaggag gatetecace atcetetttg gegetgegta cacetgettg 1140 gaggctgcaa cggggcgggc tctgctgcgt caacacatgg acatcactgg agaggaaaac 1200 ccactcaaca ageteegegt gaagattgaa ccaggegttg acceggaega cacetataat 1260 gagaccccct acgagaaagg tttctgcttt gtctcatacc tggcccactt ggtgggtgat 1320 caggatcagt ttgacagttt tctcaaggcc tatgtgcatg aattcaaatt ccgaagcatc 1380 ttagccgatg actttctgga cttctacttg gaatatttcc ctgagcttaa gaaaaagaga 1440

WO 2005/031359 PCT/EP2004/010388

gtggatatca ttccaggttt tgagtttgat cgatggctga atacccccgg ctggcccccg 1500 tacctccctg atctctcccc tggggactca ctcatgaagc ctgctgaaga gctagcccaa 1560 ctgtgggcag ccgaggagct ggacatgaag gccattgaag ccgtggccat ctctccctgg 1620 aagacctacc agctggtcta cttcctggat aagatcctcc agaaatcccc tctccctcct 1680 gggaatgtga aaaaacttgg agacacatac ccaagtatct caaatgcccg gaatgcagag 1740 ctccggctgc gatggggcca aatcgtcctt aagaacgacc accaggaaga tttctggaaa 1800 gtgaaggagt tcctgcataa ccaggggaag cagaagtata cacttccgct gtaccacgca 1860 atgatgggtg gcagtgaggt ggcccagacc ctcgccaagg agacttttgc atccaccgcc 1920 tcccagctcc acagcaatgt tgtcaactat gtccagcaga tcgtggcacc caagggcagt 1980 tagaggeteg tgtgcatgge ecetgeetet teaggetete caggetttea gaataattgt 2040 ttgttcccaa attcctgttc cctgatcaac ttcctggagt ttatatcccc tcaggataat 2100 ctattctcta gcttaggtat ctgtgactct tgggcctctg ctctggtggg aacttacttc 2160 tctatagccc actgagcccc gagacagaga acctgcccac agctctcccc gctacaggct 2220 gcaggcacgc agggcagcgg gtattctcct cccacctaag tctctgggaa gaagtggaga 2280 ggactgatgc tettetttt tetetttetg teettttet tgetgattta tgcaaaggge 2340 tggcattctg atgcttttca ggtttaatcc ttattttaat aaagttttca agcaaaaaa 2400

<210> 2

<211> 360

<212> PRT

<213> Homo sapiens

<400> 2

145

Met Pro Pro Ser Phe Pro Phe Gly Gly Met Glu Asn Pro Cys Leu Thr 10 Phe Val Thr Pro Cys Leu Leu Ala Gly Asp Arg Ser Leu Ala Asp Val 25 Ile Ile His Glu Ile Ser His Ser Trp Phe Gly Asn Leu Val Thr Asn 40 Ala Asn Trp Gly Glu Phe Trp Leu Asn Glu Gly Phe Thr Met Tyr Ala 55 Gln Arg Arg Ile Ser Thr Ile Leu Phe Gly Ala Ala Tyr Thr Cys Leu 70 75 80 65 Glu Ala Ala Thr Gly Arg Ala Leu Leu Arg Gln His Met Asp Ile Thr 85 90 Gly Glu Glu Asn Pro Leu Asn Lys Leu Arg Val Lys Ile Glu Pro Gly 105 100 Val Asp Pro Asp Asp Thr Tyr Asn Glu Thr Pro Tyr Glu Lys Gly Phe 120 Cys Phe Val Ser Tyr Leu Ala His Leu Val Gly Asp Gln Asp Gln Phe 135

Asp Ser Phe Leu Lys Ala Tyr Val His Glu Phe Lys Phe Arg Ser Ile

155

160

150

<211> 25 <212> DNA

<213> artificial sequence

Leu	Ala	Asp	Asp	Phe	Leu	Asp	Phe	Tyr	Leu	Glu	Tyr	Phe	Pro	Glu	Leu		
				165					170					175			
Lys	Lys	Lys	Arg	Val	Asp	Ile	Ile	Pro	Gly	Phe	Glu	Phe	Asp	Arg	Trp		
			180					185		•			190				
Leu	Asn	Thr	Pro	Gly	Trp	Pro	Pro	Tyr	Leu	Pro	Asp	Leu	Ser	Pro	Gly		
		195					200					205	•				
qeA	Ser	Leu	Met	Lys	Pro	Ala	Glu	Glu	Leu	Ala	Gln	Leu	Trp	Ala	Ala		
	210					215					220						
Glu	Glu	Leu	Asp	Met	Lys	Ala	Ile	Glu	Ala	Val	Ala	Ile	Ser	Pro	Trp		
225		٠			230					235					240		
Lys.	Thr	Tyr	Gln	Leu	Val	Tyr	Phe	Leu	Asp	Lys	Ile	Leu	Gln	Lys	Ser		
			•	245		•			250					255	•		
Pro	Leu	Pro	Pro	Gly	Asn	Val	Lys	Lys	Leu	Gly	Asp	Thr	Tyr	Pro	Ser	•	
	•		260					265					270				
Ile	Ser	Asn	Ala	Arg	Asn	Ala	Glu	Leu	Arg	Leu	Arg	Trp	Gly	Gln	Ile		
		275					280					285					٠.
Val	Leu	Lys	Asn	Asp	His	Gln	Glu	Asp	Phe	Trp	Lys	Val	Lys	Glu	Phe		
	290					295					300						
Leu	His	Asn	Gln	Gly	Lys	Gln	Lys	Tyr	Thr	Leu	Pro	Leu	Tyr	His	Ala		
305					310					315				٠	320		
Met	Met	Gly	Gly	Ser	Glu	Val	Ala	Gln	Thr	Leu	Ala	Lys	Glu	Thr	Phe		
				325					330					335			
Ala	Ser	Thr	Ala	Ser	Gln	Leu	His	Ser	Asn	Val	Val	Asn	Tyr	Val	Gln		•
			340					345					350				
Gln	Ile	Val	Ala	Pro	Lys	Gly	Ser										
		355					360										
<210)> 3	3															
<211	.> 2	21															
<212> DNA																	
<213	> ε	rtiț	icie	al se	dre	ıce											
<220)>		•										•				
<223	> 1	orwa	rd p	rime	er												
<400																	_
gaagattgaa ccaggcgttg a . 2											21						
.010						•											
<210	> 4	ŧ															

PCT/EP2004/010388

	<220>	·					
	<223>	reverse primer					
	<400>						
	ggtatg	agac aaagcagaaa ccttt	25				
	.<210>	5					
	<211>	30	•				
	<212>	DNA					
	<213>	artificial sequence					
	<220>						
	<223>	probe					
	<400>	5					
ccggacgaca cctataatga gaccccctac							